Ciphergen Has 'Substantial Doubts' About Its Ability to Stay in Business; May Need to Raise Cash to Stay Afloat | GenomeWeb
NEW YORK (GenomeWeb News) — Ciphergen Biosystems and its outside auditor are concerned that the company may not be able to continue operating as a going concern, the firm said in its annual report it filed with the US Securities and Exchange Commission.  
 
“We believe that our current cash balances may not be sufficient to fund planned expenditures,” Ciphergen reported in the filing, released on April 2. “This raises substantial doubt about our ability to continue as a going concern.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.